Detalles de la búsqueda
1.
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease.
Am J Trop Med Hyg
; 107(5): 1091-1098, 2022 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36122681
2.
Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.
Vaccine X
; 5: 100060, 2020 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32337506
3.
Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania.
Onderstepoort J Vet Res
; 86(1): e1-e8, 2019 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30843406
4.
Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.
Vaccine
; 34(4): 523-530, 2016 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26706271
5.
Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.
Vaccine
; 32(20): 2345-9, 2014 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24462482
Resultados
1 -
5
de 5
1
Próxima >
>>